
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is a potential stock to buy as it has a large market potential with the company's focus on developing cannabinoid-based treatments, including its investigational drugs targeting Alzheimer's disease, which has no known cure, slow progression, or means of prevention. The ongoing Phase 2 trial for IGC-AD1 has reported positive interim results, demonstrating a clinical and statistically significant reduction in agitation. With upcoming milestones for the completion of its CALMA trial, and the release of its AI beta program in mid-2026, and a current attractive valuation, IGC Pharma presents high rewards for the risks and potential catalysts for the stock.
Bears say
IGC Pharma is facing a shift in their fiscal year and may face challenges in accurately reporting financial data and projecting future earnings as a result. Furthermore, despite recent progress in patient enrollment for their Phase 2 CALMA trial, the company's investigational drugs are yet to be proven effective and face potential regulatory hurdles. These factors contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares